Travere Therapeutics Company Insiders
| TVTX Stock | USD 20.53 0.30 1.44% |
Travere Therapeutics employs about 385 people. The company is managed by 15 executives with a total tenure of roughly 899 years, averaging almost 59.0 years of service per executive, having 25.67 employees per reported executive. Break down of Travere Therapeutics' management performance can provide insight into the company performance.
Travere |
Travere Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2315) % which means that it has lost $0.2315 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4675) %, meaning that it created substantial loss on money invested by shareholders. Travere Therapeutics' management efficiency ratios could be used to measure how well Travere Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Travere Therapeutics Workforce Comparison
Travere Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 7,677. Travere Therapeutics holds roughly 385 in number of employees claiming about 5% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.38) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.79) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.79. Travere Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Travere Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Travere Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Travere Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Travere Therapeutics Notable Stakeholders
A Travere Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Travere Therapeutics often face trade-offs trying to please all of them. Travere Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Travere Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Eric Dube | CEO President | Profile | |
| Elizabeth JD | General VP | Profile | |
| Elizabeth Reed | General VP | Profile | |
| Sandra Calvin | Corporate SVP | Profile | |
| William Rote | Senior Development | Profile | |
| CFA CFA | Chief Officer | Profile | |
| Angela Giannantonio | Senior Resources | Profile | |
| Jula MD | Chief Officer | Profile | |
| Casey Logan | Chief Officer | Profile | |
| Nivi Nehra | Vice Relations | Profile | |
| Christopher CFA | Chief Officer | Profile | |
| Charlotte Smith | Senior Affairs | Profile | |
| Noah MD | Ex Advisor | Profile | |
| Naomi Eichenbaum | Vice Relations | Profile | |
| Peter Heerma | Chief Officer | Profile |
About Travere Therapeutics Management Performance
The success or failure of an entity such as Travere Therapeutics often depends on how effective the management is. Travere Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Travere management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Travere management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Travere Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 310 people.
Please note, the imprecision that can be found in Travere Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Travere Therapeutics. Check Travere Therapeutics' Beneish M Score to see the likelihood of Travere Therapeutics' management manipulating its earnings.
Travere Therapeutics Workforce Analysis
Traditionally, organizations such as Travere Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Travere Therapeutics within its industry.Travere Therapeutics Manpower Efficiency
Return on Travere Therapeutics Manpower
| Revenue Per Employee | 605.6K | |
| Revenue Per Executive | 15.5M | |
| Net Loss Per Employee | 832.8K | |
| Net Loss Per Executive | 21.4M | |
| Working Capital Per Employee | 560.9K | |
| Working Capital Per Executive | 14.4M |
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.